Search Results 251-260 of 15280 for TNF

1. Nutrition and healthy eating LGBTQ health - Mayo Clinic

   You can master healthy eating by learning how to plan meals and shop smart, and by practicing healthy-cooking techniques.

2. A Study of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease - Mayo Clinic

   ... TNF-α antagonist or vedolizumab or ustekinumab, or having documented intolerance. Women of childbearing potential (WCBP) must have negative serum pregnancy ...

3. Nutrition and healthy eating - Mayo Clinic

   You can master healthy eating by learning how to plan meals and shop smart, and by practicing healthy-cooking techniques.

4. A Study to Evaluate the Safety, Tolerability, and Clinical Benefit of AK002 in Adult Patients with Mast Cell Gastritis and/or Gastroenteritis

   ... TNF, anti-IL-5, anti-IL-5 receptor, dupilumab, anti-IgE antibodies, omalizumab) or systemic corticosteroids with a daily dose >10 mg of prednisone or ...

5. Physical Medicine and Rehabilitation Physicians - Medical Professionals - Mayo Clinic

   Find physical medicine and rehabilitation Physicians at your nearest Mayo Clinic location. Learn about the conditions they treat and procedures performed.

6. Publications - Patricio Escalante, M.D., M.S. - Mayo Clinic

   Diagnosis and Management of Latent Tuberculosis and Tuberculosis in Candidates for TNF-alpha Antagonist Therapy: An Expert Survey J of Mycobac Dis.2014, Oct ...

7. Untitled

   Page 1.

8. Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer - Mayo Clinic

   ... tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1: Patients who have received acute, low dose, systemic immunosuppressant ...

9. A Study to Evaluate Chemoradiotherapy with or without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer - Mayo Clinic

   ... tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization. Exceptions: Patients may have received acute, low dose, systemic ...

10. A Study to Evaluate the Effectiveness and Safety of Obeticholic Acid to Treat Patients with Primary Sclerosing Cholangitis - Mayo Clinic

    Subjects being administered biologic treatments (eg, anti-tumor necrosis factor (TNF) or anti-integrin monoclonal antibodies), immunosuppressants, systemic ...